Of these, EGFR-tyrosine kinase inhibitor (TKI) was recommended by treatment guidelines as first-line treatment for EGFR-mutated advanced non-small cell lung cancer (Hanna et al., 2017; Clinical Practice Gu, 2018; Wu et al., 2019a). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.